Merck & Co., Inc. Amortization
Merck & Co., Inc. (MRK) reported Amortization of $1.92 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2026-08-07
- Merck & Co., Inc. amortization for the quarter ending 2026-06-30 was $984.00M, a 63.73% increase year-over-year.
- Merck & Co., Inc. amortization for the quarter ending 2026-03-31 was $931.00M, a 55.95% increase year-over-year.
- Merck & Co., Inc. amortization for the quarter ending 2025-12-31 was $973.00M, a 44.15% increase year-over-year.
- Merck & Co., Inc. amortization for the quarter ending 2025-09-30 was $622.00M, a 1.74% decline year-over-year.
- Merck & Co., Inc. amortization for fiscal 2025 was $2.79B, a 16.62% increase from fiscal 2024.
- Merck & Co., Inc. amortization for fiscal 2024 was $2.40B, a 17.17% increase from fiscal 2023.
- Merck & Co., Inc. amortization for fiscal 2023 was $2.04B, a 1.97% decline from fiscal 2022.
- Merck & Co., Inc. amortization for fiscal 2022 was $2.08B, a 27.44% increase from fiscal 2021.
| Period end | Amortization 3 month | Amortization 3 month as first filed | Amortization 6 month | Amortization 9 month | Amortization 12 month | Amortization 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $984.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.92B 10-Q · filed 2026-08-07 | $2.89B derived: sum of 3 quarters · filed 2026-08-07 | $3.51B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $931.00M 10-Q · filed 2026-05-04 | $1.90B derived: sum of 2 quarters · filed 2026-05-04 | $2.53B derived: sum of 3 quarters · filed 2026-05-04 | $3.13B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $973.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.59B derived: sum of 2 quarters · filed 2026-02-24 | $2.20B derived: sum of 3 quarters · filed 2026-08-07 | $2.79B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $622.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.22B derived: sum of 2 quarters · filed 2026-08-07 | $1.82B 10-Q · filed 2025-11-05 | $2.50B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $601.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.20B 10-Q · filed 2026-08-07 | $1.87B derived: sum of 3 quarters · filed 2026-08-07 | $2.51B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $597.00M 10-Q · filed 2026-05-04 | $1.27B derived: sum of 2 quarters · filed 2026-05-04 | $1.91B derived: sum of 3 quarters · filed 2026-05-04 | $2.52B derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $675.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.31B derived: sum of 2 quarters · filed 2026-02-24 | $1.92B derived: sum of 3 quarters · filed 2026-02-24 | $2.40B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $633.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.25B derived: sum of 2 quarters · filed 2025-11-05 | $1.72B 10-Q · filed 2025-11-05 | $2.18B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $614.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.09B 10-Q · filed 2025-08-05 | $1.55B derived: sum of 3 quarters · filed 2026-02-24 | $2.11B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $473.00M 10-Q · filed 2025-05-02 | $935.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.50B derived: sum of 3 quarters · filed 2026-02-24 | $1.97B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $462.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.02B derived: sum of 2 quarters · filed 2026-02-24 | $1.50B derived: sum of 3 quarters · filed 2026-02-24 | $2.04B 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $562.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.04B derived: sum of 2 quarters · filed 2024-11-06 | $1.58B 10-Q · filed 2024-11-06 | $2.04B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-06-30 | $477.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.02B 10-Q · filed 2024-08-05 | $1.48B derived: sum of 3 quarters · filed 2025-02-25 | $1.94B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-03-31 | $543.00M 10-Q · filed 2024-05-03 | $1.00B derived: sum of 2 quarters · filed 2025-02-25 | $1.47B derived: sum of 3 quarters · filed 2025-02-25 | $1.93B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $462.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $922.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.39B derived: sum of 3 quarters · filed 2025-02-25 | $2.08B 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $460.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $924.00M derived: sum of 2 quarters · filed 2023-11-03 | $1.62B 10-Q · filed 2023-11-03 | $2.03B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | $464.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.16B 10-Q · filed 2023-08-07 | $1.57B derived: sum of 3 quarters · filed 2024-02-26 | $1.93B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $699.00M 10-Q · filed 2023-05-05 | $1.10B derived: sum of 2 quarters · filed 2024-02-26 | $1.46B derived: sum of 3 quarters · filed 2024-02-26 | $1.82B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $405.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $765.00M derived: sum of 2 quarters · filed 2024-02-26 | $1.12B derived: sum of 3 quarters · filed 2024-02-26 | $1.64B 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $360.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $717.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.23B 10-Q · filed 2022-11-03 | $1.66B derived: sum of 4 quarters · filed 2023-02-24 | ||
| 2021-06-30 | $357.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $871.00M 10-Q · filed 2022-08-05 | $1.29B derived: sum of 3 quarters · filed 2023-02-24 | $1.70B derived: sum of 4 quarters · filed 2023-02-24 | ||
| 2021-03-31 | $514.00M 10-Q · filed 2022-05-05 | $534.00M 10-Q · filed 2021-05-05 | $938.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.34B derived: sum of 3 quarters · filed 2023-02-24 | $1.92B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $424.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $829.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.41B derived: sum of 3 quarters · filed 2023-02-24 | $1.82B 10-K · filed 2023-02-24 | $1.90B 10-K · filed 2021-02-25 | |
| 2020-09-30 | $405.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $983.00M derived: sum of 2 quarters · filed 2021-11-05 | $1.39B 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $578.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $988.00M 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $410.00M 10-Q · filed 2021-05-05 | |||||
| 2019-12-31 | $1.70B 10-K · filed 2022-02-25 | $1.97B 10-K · filed 2021-02-25 | ||||
| 2018-12-31 | $3.10B 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |